Tirzepatide Trial Investigates Impact on Fatty Liver Disease in Diabetic Patients

Obesity and Type 2 Diabetes Mellitus (T2DM) are rapidly increasing globally, with Non-alcoholic Fatty Liver Disease (NAFLD) affecting over 30% of T2DM patients and 50% of obese individuals. NAFLD can progress to Non-alcoholic Steatohepatitis (NASH), a severe form leading to liver failure or hepatocellular carcinoma. Currently, there are no randomized studies on NASH treatment in the UAE population, creating a significant knowledge gap for this specific demographic.

The study, currently underway, aims to demonstrate the significant efficacy of Tirzepatide in reducing liver fat deposition in patients with Type 2 Diabetes and NAFLD with advanced fibrosis. Based on Tirzepatide's well-established metabolic benefits, including its potent effects on glucose homeostasis and weight loss, researchers strongly hypothesize a substantial improvement in various liver health markers over the six-month treatment period. > The primary objective is to observe a substantial reduction in liver fat content, potentially leading to the reversal or stabilization of NAFLD and NASH progression, thereby preventing more severe liver complications. Secondary anticipated findings include significant improvements in glycemic control, with expected reductions in HbA1c levels, and notable body weight loss, both well-established effects of GIP/GLP-1 agonism. This trial seeks to provide the first randomized, quantitative data on NASH treatment specifically within the UAE population, aiming to precisely quantify these expected benefits.